Clinical Trials Logo

Fallopian Tube Neoplasms clinical trials

View clinical trials related to Fallopian Tube Neoplasms.

Filter by:

NCT ID: NCT01940172 Completed - Clinical trials for Relapsed Fallopian Tube Cancer

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Start date: November 2013
Phase: Phase 1
Study type: Interventional

This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.

NCT ID: NCT01905163 Completed - Ovarian Cancer Clinical Trials

Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients

CILOVE
Start date: August 2013
Phase: Phase 2
Study type: Interventional

This prospective nonrandomized multicenter phase II study, will evaluate the possibility of performing a laparoscopic interval debulking after a minimum of 3 cycles of chemotherapy in highly chemo-sensitive patients with advanced ovarian, tubal cancer or primary peritoneal.

NCT ID: NCT01899599 Completed - Clinical trials for Fallopian Tube Cancer

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Start date: September 2013
Phase: Phase 2
Study type: Interventional

Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.

NCT ID: NCT01891344 Completed - Ovarian Cancer Clinical Trials

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

ARIEL2
Start date: October 30, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

NCT ID: NCT01853644 Completed - Clinical trials for Recurrent Fallopian Tube Cancer

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

TIVO
Start date: June 6, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01846611 Completed - Ovarian Neoplasms Clinical Trials

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Start date: October 16, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

NCT ID: NCT01764802 Completed - Breast Cancer Clinical Trials

Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

NCT ID: NCT01749397 Completed - Clinical trials for Stage IV Ovarian Cancer AJCC v6 and v7

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Start date: December 7, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of veliparib when given together with floxuridine in treating patients with epithelial ovarian, primary peritoneal cavity, or fallopian tube cancer that has spread to other places in the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with floxuridine may kill more tumor cells.

NCT ID: NCT01747798 Completed - Clinical trials for Recurrent Ovarian Epithelial Cancer

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Start date: November 2, 2012
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin, may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube cancer.

NCT ID: NCT01709487 Completed - Clinical trials for Primary Peritoneal Carcinoma

Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal chemotherapy (HIPEC) after optimal debulking.